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Apoptosis: Bcl-2-related proteins get connected
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Bcl-2 family proteins are key intracellular regulators of
programmed cell death. Several recent discoveries
demonstrate how these proteins interact with the
molecular machinery that controls and executes the
cell-death programme, and how they can themselves be
regulated by extracellular survival signals.
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All nucleated animal cells seem to have the capacity to
undergo programmed cell death, a process of cell suicide
with distinctive morphological features known as
apoptosis. The fate of a particular cell — whether it lives
or dies — is regulated by extracellular signals from other
cells. An evolutionarily conserved family of intracellular
proteases, called caspases, lies at the heart of the cell-
death programme and is responsible for the ultimate
destruction of the cell. The importance of tightly regulat-
ing the cell-death programme is obvious — but what is its
molecular basis?
The first important clues about the molecular basis of
programmed cell death came from genetic studies of the
nematode Caenorhabditis elegans (reviewed in [1]). Two
genes, ced-3 and ced-4, are needed for all programmed cell
deaths that occur during the worm’s development,
whereas another gene, ced-9, suppresses the action of ced-3
and ced-4 in cells that survive. Vertebrate homologues
have been identified for ced-3, which encodes a caspase,
and for ced-9, which is related to the bcl-2 gene that was
first identified in mammals as a proto-oncogene, but no
vertebrate homologue has yet been found for ced-4. 
A number of Bcl-2-related proteins have been identified
in mammals [2]. Some, such as Bcl-2 and Bcl-XL, inhibit
programmed cell death, whereas others, such as Bax and
Bak, promote programmed cell death (Fig. 1). The various
Bcl-2 family members can dimerize, thereby antagonizing
or enhancing each other’s function. But the most impor-
tant questions about these proteins have remained unan-
swered. How do they regulate the activation of caspases,
and how are they themselves regulated? 
I shall discuss three recent advances in our understanding
of Bcl-2 proteins. First, and most exciting, is the finding
that the Bcl-2 proteins CED-9 and Bcl-XL can physically
interact with the C. elegans cell-death protein CED-4,
which itself binds directly to caspases. Second is the
finding that Bcl-2 and Bcl-XL regulate the release of
cytochrome c from mitochondria to the cytosol, thereby
preventing the activation of caspases by cytochrome c.
Third is the finding that Bcl-2 proteins can be regulated
by phosphorylation, providing a link from extracellular
signals, via intracellular kinase-mediated signalling
cascades, to the machinery that actually kills the cell.
Interactions between Bcl-2 proteins, CED-4 and caspases
The recent discovery that CED-9 physically interacts with
CED-4 [3–6] and, furthermore, that CED-4 can indepen-
dently bind to CED-3/caspases [5], provides the first
physical link between Bcl-2 proteins and the cell-death
machinery. The new findings suggest that Bcl-2 proteins
directly regulate the activation of caspases via CED-4,
which acts as an adaptor protein. This model is consistent
with genetic studies of programmed cell death in 
C. elegans, which had already suggested that CED-4 acts
Figure 1
Genetic analysis in the nematode C. elegans
suggests that ced-9, which encodes a Bcl-2-
related protein, acts upstream of ced-4 and
ced-3; consistent with this, Bcl-2 and Bcl-XL
have been found to act biochemically
upstream of some of the caspases.
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between CED-9 and CED-3, with CED-9 upstream 
(Fig. 1). CED-4 is required, for example, for CED-9 to
inhibit CED-3; indeed, splicing variants of CED-4 deter-
mine whether CED-9 activates or suppresses cell death.
The model is also consistent with the biochemical
evidence that Bcl-2 and Bcl-XL act upstream of some of
the caspases in mammalian cells.
The physical association between CED-9 and CED-4 was
demonstrated by complementary techniques — yeast two-
hybrid assays [3,4,6], coimmunoprecipitation [4–6] and
colocalization [3,6]. When expressed in transfected
mammalian cells, CED-4 induces programmed cell death
[5]; this can be blocked both by caspase inhibitors and
CED-9, indicating that CED-4 can act in mammalian cells
in the same way that it does in C. elegans. Furthermore,
Bcl-XL can also bind to CED-4, and, like CED-9, it
inhibits CED-4 function [5]. Mutations in CED-9 or 
Bcl-XL that disrupt their ability to interact with CED-4
also abolish their ability to suppress programmed cell
death [4,5]. Thus, the interactions between CED-9/Bcl-2
proteins and CED-4 are evolutionarily conserved between
nematodes and humans, strongly suggesting that there is a
CED-4 homologue in vertebrates.
How does cytosolic CED-4 induce cell death? To promote
cell death in C. elegans, CED-4 requires CED-3, and its
ability to induce programmed cell death in mammalian
cells depends on caspase activity. Chinnaiyan et al. [5]
therefore looked for evidence of a physical interaction
between CED-4 and CED-3. They found that CED-4 can
bind directly to CED-3, as well as to two mammalian cas-
pases, ICE (caspase-1) and FLICE (caspase-8), but not to
the caspases CPP32 (caspase-3) or Mch2 (caspase-6).
These interactions were independent of CED-4’s ability
to associate with CED-9; indeed, CED-9 and CED-3
could be coimmunoprecipitated from cytosol, but only if
CED-4 was coexpressed, indicating that a complex can
form containing all three proteins. 
Bcl-XL, by contrast, was able to
associate with ICE and FLICE in the
absence of CED-4, but did not bind
to them directly, indicating that an
unidentified endogenous cytosolic
factor acts as a linker. Expression of
CED-4 did not enhance this
interaction, but a truncated form of
CED-4 that can bind to CED-3 but
not CED-9 disrupted it, providing
further support for the idea that the
endogenous linking protein might be
a CED-4 homologue. The next step
will be to identify and characterize
this protein and to determine whether
it is indeed a mammalian CED-4. The
identification of specific regions of
two independent types of interacting protein —
CED-9/Bcl-2 proteins and caspases — will greatly
facilitate this search.
CED-4’s ability to interact with CED-3, ICE and FLICE
was found to depend on the presence of a large amino-
terminal domain, known as the pro-domain, that is present
in these caspases and is cleaved off when they are acti-
vated by proteolytic cleavage. Both of the non-interacting
caspases, CPP32 and Mch2, have small pro-domains,
whereas CED-3, ICE and FLICE all have large pro-
domains. Even in isolation from the rest of the protein, the
pro-domain of CED-3 could associate with CED-4, sug-
gesting that this region of the protein is in important site
of interaction.
The subcellular localization of CED-4 is consistent with a
physical interaction with CED-9/Bcl-2 proteins in vivo.
When expressed in yeast or mammalian cells, CED-4 is
cytosolic, but when coexpressed with CED-9, it localizes
to the same intracellular sites as CED-9 [3,6]. Binding to
CED-9 (or Bcl-XL) thus sequesters CED-4 from the
cytosol and inhibits its ability to activate caspases. The
simplest model consistent with these findings (Fig. 2) is
that anti-apoptotic CED-9/Bcl-2 proteins sequester inac-
tive pro-CED-3/caspases, via CED-4 linker proteins, at
intracellular membrane sites, thereby preventing them
from activating downstream cytosolic caspases.
This model for inhibition of caspases is reminiscent of the
way the cell-surface receptor CD95 (Fas/Apo-1) activates
the caspase FLICE by recruiting pro-FLICE to a protein
complex at the plasma membrane and releasing active
FLICE into the cytosol (reviewed in [7]). The active
CD95 complex recruits adaptor proteins that bind to the
FLICE pro-domain. Interestingly, the ‘death effector
domains’ in the pro-domain of FLICE and in the adaptor
protein FADD/MORT1 both have sequence similarities
to a region of CED-4, which had suggested that these 
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Figure 2
A model of caspase regulation by Bcl-2 proteins. See text for details.
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proteins might physically interact [7]. The idea that Bcl-2
proteins regulate the death programme by controlling the
ability of CED-4 to activate caspases is supported by the
observation that pro-apoptotic Bcl-2 proteins disrupted
the interaction between Bcl-XL and CED-4, without
themselves binding to CED-4 [5]; presumably their
binding to Bcl-XL displaces CED-4 (Fig. 2).
Bcl-2 can block release of cytochrome c from mitochondria
Since Bcl-2 was shown to be localized to mitochondrial
membranes, these organelles have often been at the
centre of attention and controversy in the cell-death field;
they have also been involved in many false leads and pur-
ported breakthroughs in our understanding of Bcl-2 func-
tion. Two recent papers, by Yang et al. [8] and by Kluck et
al. [9], have now provided convincing evidence suggesting
that mitochondria may play a direct role in programmed
cell death, by releasing cytochrome c in response to death-
inducing signals. By inhibiting this release, Bcl-2 and 
Bcl-XL may prevent cytochrome c from activating
caspases in the cytosol, and thereby suppress programmed
cell death.
Several lines of evidence indicated that mitochondria are
important for Bcl-2 function. Removal of the carboxy-
terminal, membrane-targeting domain of Bcl-2 inhibits its
ability to suppress programmed cell death, and targeting
the protein to a specific organelle — mitochondria or
endoplasmic reticulum (ER) — seems to be necessary for
it to work [10]. One of the most convincing pieces of evi-
dence that mitochondria are important for Bcl-2 function
comes from studying a cell-free programmed cell death
system based on Xenopus egg extracts, where it has been
found that Bcl-2 can inhibit nuclei from undergoing apop-
totic changes only if a mitochondrial fraction is also
present [11]. Which of the many mitochondrial functions
are important for programmed cell death?
Kroemer et al. [12] have suggested that the loss of
mitochondrial membrane potential and the opening of
large pores, called permeability transition channels, is
important during programmed cell death. Bcl-2 can inhibit
both this loss of membrane potential and the release of
factors from mitochondria into the cytosol that can activate
caspases [13]. The idea that the release of mitochondrial
caspase-activating proteins might be an important point of
control by Bcl-2 proteins gained further support when Liu
et al. [14] purified proteins released from mitochondria in a
cell-free programmed cell death system and identified one
of them as cytochrome c.
Yang et al. [8] and Kluck et al. [9] have now extended this
finding. Both groups found that Bcl-2 and Bcl-XL pre-
vented cytochrome c release upon induction of pro-
grammed cell death in intact cells and cell-free systems.
Bcl-2 and Bcl-XL were effective only on the mitochondria
on which they were located [9], and they could not inhibit
apoptotic changes induced by cytochrome c after it was
released or if it was added exogenously, supporting the
idea that they exert their effect on mitochondria rather
than the cytosol. The released cytochrome c appears to
cooperate with other cytosolic factors to activate caspases,
and may thereby induce programmed cell death:
cytochrome c, in the presence of cytosol, can activate
CPP32 in vitro [14], and caspase inhibitors can block pro-
grammed cell death in cells even under conditions in
which cytochrome c is released into the cytosol [9]. Impor-
tantly, both groups observed cytochrome c release without
loss of mitochondrial membrane potential, which suggests
that the potential loss is not required for programmed cell
death and rules out the possibility that cytochrome c
release requires opening of the permeability transition
channels or is simply an artefact of mitochondrial damage,
which would also cause loss of membrane potential.
The idea that a cytochrome might be important in the
suppression of programmed cell death by Bcl-2 proteins
was previously suggested, again by evidence from 
C. elegans, where ced-9 is in the same transcription unit as a
cytochrome-encoding gene [15]. Cytochrome c can now
be added to the list of important biochemical elements of
the cell-death machinery, and many new questions are
raised. What is the mechanism by which cytochrome c is
released from mitochondria, and how do Bcl-2 and Bcl-XL
prevent this release? How does cytochrome c activate
caspases? Does the ER similarly release a caspase-
activating factor into the cytosol? One speculation is that
ion homeostasis in mitochondria might be involved in
some way, a notion supported by the observed pore-like
structure [16] and ion-channel-forming properties [17] of
Bcl-XL. This pore-like structure has also raised the possi-
bility that these Bcl-2 proteins might, like the pore-
forming protein perforin, regulate the passage of proteins
involved in activating the death programme [18].
Post-translational regulation of Bcl-2 proteins
We have seen that Bcl-2 proteins are important guardians
of the death programme: they control at least two caspase-
activating proteins and, at least where it has been possible
to test the hypothesis, as in C. elegans, they are essential for
cell survival. But what controls the guardians? If, as seems
likely, extracellular signals are required to suppress the
death programme in every cell, then one would expect
these signals to work, at least in part, by regulating Bcl-2
proteins. One way of doing this is by phosphorylation: it is
clear that Bcl-2 can be phosphorylated on serine residues
in response to a variety of stimuli (reviewed in [19]). Phos-
phorylation of Bcl-2 occurs within a flexible loop region
which appears to be a regulatory domain. Deletion of this
loop domain enhances the action of Bcl-2 and Bcl-XL as
suppressors of programmed cell death and enables Bcl-2
to suppress programmed cell death in at least one case
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where it is normally ineffective [20]. Bcl-2 proteins may
also be regulated by proteolytic cleavage: Bcl-2 can be
cleaved by human immunodeficiency virus-1 (HIV-1) pro-
teases in vitro, and is cleaved during HIV-1-infection of
lymphocytes, which may explain how these cells are
induced to die [21] though it is not clear whether Bcl-2
cleavage is absolutely required for the apoptotic death of
HIV-infected cells.
The regulation of Bcl-2 proteins by post-translational
modification helps to resolve several puzzling observa-
tions. The relative levels of anti-apoptotic and pro-apop-
totic Bcl-2 proteins can influence the propensity of a cell
to live or die, for example, but this is not always an accu-
rate predictor: there are cases where Bcl-2 overexpression
does not protect against programmed cell death, or where
one programmed-cell-death-suppressor is effective but
another is not (reviewed in [19]). Furthermore, some sur-
vival factors can work independently of the levels of Bcl-2
proteins — this is true of the protection of fibroblasts by
insulin-like growth factor 1 (IGF-1) [22] and of ciliary
neurons by ciliary neurotrophic factor (CNTF) [23]. Many
of these seemingly contradictory observations make more
sense if one considers that Bcl-2 proteins can be modu-
lated by post-translational modifications.
Do such modifications also provide a link between extra-
cellular and intracellular regulators of cell survival and
death? The best evidence for such a link comes from a
study by Zha et al. [24], which suggests that the cytokine
interleukin-3 (IL-3) promotes cell survival by phos-
phorylating the pro-apoptotic protein Bad (see Fig. 3). Bad
lacks the hydrophobic domain that
targets most other Bcl-2 family pro-
teins to intracellular membranes. The
non-phosphorylated form of Bad
antagonizes Bcl-2 and Bcl-XL by
heterodimerizing with them at intra-
cellular membrane sites, thereby pro-
moting programmed cell death. IL-3
promotes cell survival by inducing
phosphorylation of Bad, causing it to
dissociate from Bcl-XL and thereby
releasing Bcl-XL’s protective func-
tion. Phosphorylated Bad appears to
be sequestered in the cytosol, and
prevented from binding to Bcl-XL, by
binding to the cytosolic 14–3–3 pro-
tein. Mutation of the phosphorylation
sites on Bad prevents its binding to
14–3–3 and enhances its activity in
promoting programmed cell death.
Thus, IL-3 seems to promote cell sur-
vival by activating kinases that phos-
phorylate and thereby inactivate Bad. 
Bad phosphorylation and cell survival can also be pro-
moted by activation of Raf-1 [25], a serine/threonine
kinase which normally forms part of the mitogen-activated
protein (MAP) kinase cascade and which is activated by
Ras-dependent signalling pathways. Raf-1 can associate
with Bcl-2 in vivo [26], suggesting that it might activate a
kinase cascade associated in a complex with Bcl-2 at mito-
chondrial and other intracellular membrane sites, resulting
in phosphorylation of Bad and promotion of cell survival.
A molecular framework for programmed cell death
It thus seems clear that phosphorylation of Bcl-2 proteins is
one way that the cell-death programme is regulated and is
an important way by which some survival factors can sup-
press programmed cell death. The recent discoveries con-
cerning CED-4 and cytochrome c indicate at least two ways
that Bcl-2 proteins regulate caspase activation: by binding
to and inhibiting CED-4, and by preventing the release of
cytochrome c into the cytosol. The genetics of programmed
cell death in C. elegans have thus proved powerfully predic-
tive. Now, at last, the molecular framework of programmed
cell death and its regulation are falling into place.
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Figure 3
A model of Bcl-XL regulation by Bad phosphorylation. See text for details.
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